Screener / SEC EDGAR /CIK 0001581280 /10-K filed Nov 17, 2025, compared with Nov 18, 2024 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Twist Bioscience Corp TWST

Compare with peers Embed
The 10-K against last year's

154 changes: 26 added, 37 removed, 86 reworded, 5 quiet changes

10-K Nov 17, 2025 vs Nov 18, 2024

10-K 0001581280-25-000025 (Nov 17, 2025) vs 10-K 0001628280-24-048262 (Nov 18, 2024)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

254 paragraphs · 14 new · 92 reworded · 13 gone · 10-K Nov 17, 2025 against Nov 18, 2024
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 106 · 50% changed Every version of it
Any A violation of data privacy or data protection laws could adversely harm our operating results and financial condition, damage to our reputation or brand may otherwise materially and adversely affect harm our business, financial condition and results of operations. business.
Paragraph 122 · 48% changed Every version of it
In order While we believe our current manufacturing capacity is sufficient to meet existing customer demand, we cannot predict the volume of demand we will face in the future, which may result in excess or obsolete inventory and resulting charges. If we are unable to scale our manufacturing capacity for current or future products in a timely manner to meet increased customer demand in the future, we could lose revenue, and our business, financial condition, and results of operations could be materially harmed. Our ability to successfully expand our manufacturing capacity of new and existing products, we may need to either build additional internal manufacturing capacity, contract with one or more partners, or both. Our production facility in Wilsonville, Oregon has increased our manufacturing capacity, but if customer demand increases, we may need to expand manufacturing capacity further, which could impact our revenue growth. is not guaranteed. Our technology and the production process for our DNA synthesis equipment and tools are complex, involving specialized parts, and we complex. We may encounter unexpected difficulties in the manufacture, improvement manufacturing, improving or increasing the capacity of our DNA synthesis equipment and tools, and addressing these difficulties may cause us to divert our time and resources from our other product offerings. There is no assurance that If we will be able to continue to increase manufacturing capacity internally or that we will find one or more suitable partners to help us towards this objective, in order to meet the volume and quality requirements necessary for success in our existing and potential markets. Manufacturing and product quality issues may arise as we continue to increase the scale of our production. If our DNA synthesis equipment and tools do not consistently produce DNA products that meet our customers’ performance expectations, our reputation may be harmed, and we may be are unable to generate sufficient revenue to become profitable. Any delay or inability in expanding expand our manufacturing capacity could diminish our ability in a timely or cost-effective manner to develop or sell our products, which could result in lost revenue and materially harm meet future demand, our business, financial condition condition, and results of operations. operations could be materially harmed.
Paragraph 79 · 47% changed Every version of it
A deterioration of our relationship with any of our suppliers, or problems experienced by these suppliers, could lead to shortages in our production capacity for some or all of our products. In such case, we may not be able to fulfill the demand of existing customers or supply new customers. In addition, shortages of raw materials or component parts or an increase in the cost of the raw materials or component parts we use could result in decreased revenue or could impair our ability to maintain or expand our business.
Paragraph 14 · 46% changed Every version of it
•We may require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on such additional financing may not be available acceptable terms, or at all, which could force us to delay, limit, reduce or terminate have an adverse effect on our product manufacturing and development and other operations; business;
Paragraph 125 · 46% changed Every version of it
We may require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on such additional financing may not be available acceptable terms, or at all, which could force us to delay, limit, reduce or terminate have an adverse effect on our product manufacturing and development and other operations. business.
Paragraph 253 · 45% changed Every version of it
Investors, stockholders, Companies across all industries and around the globe are facing increasing scrutiny relating to their ESG policies, initiatives and activities by investors, lenders, customers, suppliers government regulators and other third parties are increasingly focusing on ESG and corporate social responsibility endeavors and reporting. market participants. Certain institutional investors, investment funds, other influential investors, customers, suppliers and other third parties are also increasingly focused on ESG practices. practices and corporate social responsibility endeavors and reporting and may use these factors to guide investment strategies. In some cases, investors may choose not to invest in our company if they believe our policies relating to corporate responsibility are inadequate. In contrast, “anti-ESG” sentiment has gained momentum across the United States, with several proposed or enacted “anti-ESG” policies, legislation, or initiatives, and the U.S. federal administration having recently issued an executive order opposing diversity, equity and inclusion initiatives in the private sector. Any initiatives, goals, or commitments we disclose related to ESG matter in light of evolving, and sometimes, conflicting, laws, regulations, policies and investor and other stakeholder expectations involve risks and uncertainties and could be difficult to achieve and costly to implement. Companies that do not adapt to or comply with the evolving investor or stakeholder expectations and standards, or which are perceived to have not responded appropriately, may suffer from reputational damage and result in the business, financial condition and/or stock price of a company being materially and adversely affected. Further, this increased focus on ESG issues may result in new regulations and/or third-party requirements that could adversely impact our business, or certain stockholders reducing or eliminating their holdings of our stock. Additionally, an allegation or perception that we have not taken sufficient action in these areas could negatively harm our reputation.
Paragraph 36 · 45% changed Every version of it
We face competition from a broad range of providers of core synthetic biology products such as GenScript Biotech Corporation, DNA Script, Inc., GENEWIZ (owned by Azenta), Azenta Life Sciences), Integrated DNA Technologies, Inc. (owned by Danaher Corporation), DNA 2.0 Inc. d/b/a/ ATUM, GeneArt (owned by Thermo Fisher Scientific Inc.), Eurofins Genomics LLC, Promega Corporation, OriGene Technologies, Inc., Eurofins Genomics Blue Heron Biotech, LLC, Heron, Elegen Corporation, Ansa Biotechnologies, Inc., Telesis Bio, Inc. and others. Additionally, we compete with both large and emerging providers in the life sciences tools and diagnostics industries focused on sample preparation for NGS such as Thermo Fisher Scientific Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Roche, New England Bioloabs and Agilent. In the antibody discovery market, we compete with contract research organizations including Curia, GenScript, and Genovac (formerly part of Aldevron, LLC), and antibody discovery biotechnology companies, such as Fair Journey/Iontas, Adimab, Distributed Bio (owned by Charles River), Ablexis, Specifica, OmniAb and AbCellera Biologics Inc. In the emerging field of DNA digital data storage, we compete with Biomemory, Catalog Technologies, Inc., GenScript, various academic institutions, and other emerging competitors. We may not be successful in maintaining our competitive position for a number of reasons. Some of our current competitors, as well as many of our
Paragraph 149 · 45% changed Every version of it
Corporate tax reform, base-erosion efforts and tax transparency continue to be high priorities in many tax jurisdictions where we intend to have business operations. As a result, policies regarding corporate income and other taxes in numerous jurisdictions are under heightened scrutiny and tax reform legislation is being proposed or enacted in a number of jurisdictions. For example, Recently, in July 2025, the U.S. government enacted The One Big Beautiful Bill Act (the “OBBBA”) which includes a broad range of tax reform provisions that may affect our financial results. The OBBBA includes, among other provisions, the allowance of immediate expensing of qualifying domestic research and development expenses and permanent extensions of certain provisions within the Tax Cuts and Jobs Act of 2017, or 2017. The Company has evaluated the Tax Act, signed into law on December 22, 2017, adopting broad U.S. corporate impact of the guidance provided to date and determined that it did not have a material impact related to fiscal year ended September 30, 2025. The Company will continue to evaluate the impact of changes to various provisions that could affect our income tax reform, among other things, reduced the U.S. corporate income payable and deferred tax rate, but imposed base-erosion prevention measures on non-U.S. earnings of U.S. entities as well as a one-time mandatory deemed repatriation tax on accumulated non-U.S. earnings of U.S. entities. liability.

MD&A

76 paragraphs · 12 new · 43 reworded · 24 gone · 10-K Nov 17, 2025 against Nov 18, 2024
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 3 · 50% changed
A discussion Additional information related to the comparison of our revenues for results of operations and liquidity and capital resources between the year ended September 30, 2022 as compared to the year ended September 30, 2021 can be found on page 54 years 2024 and 2023 is included in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023 2024 filed with the SEC on November 21, 2023, or our 2023 Annual Report. U.S. Securities and Exchange Commission.
Paragraph 7 · 49% changed
Our We currently generate revenue is generated through the sale of our synthetic biology tools, such and NGS tools product lines as synthetic genes, or clonal genes and fragments, oligonucleotide pools, or oligo pools, NGS tools, DNA libraries, and well as biopharma services for antibody discovery, optimization and development ("Biopharma"). development.
Paragraph 41 · 46% changed
We recorded income tax provision of $0.6 million and $1.2 million for For the year years ended September 30, 2024 2025 and 2023, respectively. We recorded 2024, we recognized income tax benefit provisions of $10.4 $0.7 million in 2022 and $0.6 million, respectively, mainly as a result of the business acquisition of Abveris. attributable to our foreign operations.
Paragraph 32 · 42% changed
Year ended September 30, Change (in thousands, except percentages) 2025 2024 2023 2022 2024-2023 2023-2022 Gain on deconsolidation of a subsidiary Change % Selling, general and administrative $ $ $4,607 $% $ (4,607) (100)% 246,976 $218,398 $28,578 13%
Paragraph 40 · 40% changed
Year ended September 30, Change (in thousands, except percentages) 2025 2024 2023 2022 2024-2023 2023-2022 Gain on deconsolidation of a subsidiary Change % Income tax expense $ (719) $ $4,607 $% (560) $ (4,607) (100)% (159) 28%
Paragraph 33 · 40% changed
Total selling, Selling, general and administrative expenses increased 15% 13% to $247.0 million for the year ended September 30, 2025, as compared to $218.4 million for the year ended September 30, 2024, as compared to $189.7 million for the year ended September 30, 2023. 2024. The increase is primarily due to an increase in personnel costs of $37.7 million, including an increase increases in stock-based compensation expense of $24.2 million. The increase in stock-based compensation expense is primarily due to a reversal of $15.9 million in the first quarter 2023 because of employee stock forfeitures related to an acquisition performance condition not being met and the remaining increase is due to stock-based awards granted to existing and new employees during fiscal year 2024. Further, the increase is attributable to increases in outside service $12.7 million, personnel costs of $1.1 million, facilities costs of $2.3 million, marketing costs of $3.4 $6.8 million, IT services costs of $2.9 $4.0 million, marketing costs of $1.5 million and depreciation and amortization expense of $0.9 million. These increases are partially offset by the decrease in the Wilsonville manufacturing facility pre-commercialization other outside service costs of $19.3 million, which was completed when the Wilsonville manufacturing facility began shipping product in January 2023. $3.1 million.
Paragraph 62 · 40% changed
We recognize revenue for synthetic biology tools, NGS tools, and DNA libraries when control of the products is transferred to the customer and at a transaction price that is determined based on the agreed upon rates in the applicable order or master supply agreement applied to the quantity of synthetic DNA that was manufactured and shipped to the customer. The transaction price is determined based on the agreed upon rates in the purchase order or master supply agreements applied to the quantity of all the products that were manufactured and shipped to the customer. Our contracts may include one or more ordered products, and the shipment of these products comprises the performance obligation(s) under the contract. Accordingly, all of the transaction price, net of any discounts, is allocated to the performance obligation (s). agreement. Our sales are primarily subject to Ex Works (as defined in Incoterms 2010) delivery terms and revenue, other than Biopharma revenue, is recorded at the point in time when products are picked up by the customer’s freight forwarder, as we have determined that this is the point in time that product control transfers to the customer. Therefore, upon shipment of the product, there are no remaining performance obligations. Our shipping and handling activities are performed before the customer obtains control of the goods and therefore are considered a fulfillment cost. Shipping and handling fees charged to our customers are recognized as product revenue considered fulfillment costs and included in the period shipped revenue. Taxes are excluded, and the related costs for providing these services are recorded as a cost of revenue. We have elected to exclude all sales and value added taxes from the measurement of the transaction price. We have not adjusted the transaction price for no significant financing since the time period between the transfer of goods and components exist due to short payment is less than one year. We have elected the practical expedient of not disclosing the consideration allocated to remaining performance obligations and an explanation of when those amounts are expected to be recognized as revenue since the duration of our contracts is less than one year. terms.
Paragraph 23 · 37% changed
Year ended September 30, Change (in thousands, except percentages) 2025 2024 2023 2022 2024-2023 2023-2022 Gain on deconsolidation of a subsidiary Change % Revenues $ $ $4,607 $% $ (4,607) (100)% 376,572 $312,974 $63,598 20%

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

MD&A253 words changed in this paragraph; it is 44% similar to last year's version.
We recognize revenue for synthetic biology tools, NGS tools, and DNA libraries when control of the products is transferred to the customer and at a transaction price that is determined based on the agreed upon rates in the applicable order or master supply agreement applied to the quantity of synthetic DNA that was manufactured and shipped to the customer. The transaction price is determined based on the agreed upon rates in the purchase order or master supply agreements applied to the quantity of all the products that were manufactured and shipped to the customer. Our contracts may include one or more ordered products, and the shipment of these products comprises the performance obligation(s) under the contract. Accordingly, all of the transaction price, net of any discounts, is allocated to the performance obligation (s). agreement. Our sales are primarily subject to Ex Works (as defined in Incoterms 2010) delivery terms and revenue, other than Biopharma revenue, is recorded at the point in time when products are picked up by the customer’s freight forwarder, as we have determined that this is the point in time that product control transfers to the customer. Therefore, upon shipment of the product, there are no remaining performance obligations. Our shipping and handling activities are performed before the customer obtains control of the goods and therefore are considered a fulfillment cost. Shipping and handling fees charged to our customers are recognized as product revenue considered fulfillment costs and included in the period shipped revenue. Taxes are excluded, and the related costs for providing these services are recorded as a cost of revenue. We have elected to exclude all sales and value added taxes from the measurement of the transaction price. We have not adjusted the transaction price for no significant financing since the time period between the transfer of goods and components exist due to short payment is less than one year. We have elected the practical expedient of not disclosing the consideration allocated to remaining performance obligations and an explanation of when those amounts are expected to be recognized as revenue since the duration of our contracts is less than one year. terms.

Source: Item 7, 10-K 0001581280-25-000025 vs Item 7, 10-K 0001628280-24-048262

Risk Factors219 words changed in this paragraph; it is 40% similar to last year's version.
Investors, stockholders, Companies across all industries and around the globe are facing increasing scrutiny relating to their ESG policies, initiatives and activities by investors, lenders, customers, suppliers government regulators and other third parties are increasingly focusing on ESG and corporate social responsibility endeavors and reporting. market participants. Certain institutional investors, investment funds, other influential investors, customers, suppliers and other third parties are also increasingly focused on ESG practices. practices and corporate social responsibility endeavors and reporting and may use these factors to guide investment strategies. In some cases, investors may choose not to invest in our company if they believe our policies relating to corporate responsibility are inadequate. In contrast, “anti-ESG” sentiment has gained momentum across the United States, with several proposed or enacted “anti-ESG” policies, legislation, or initiatives, and the U.S. federal administration having recently issued an executive order opposing diversity, equity and inclusion initiatives in the private sector. Any initiatives, goals, or commitments we disclose related to ESG matter in light of evolving, and sometimes, conflicting, laws, regulations, policies and investor and other stakeholder expectations involve risks and uncertainties and could be difficult to achieve and costly to implement. Companies that do not adapt to or comply with the evolving investor or stakeholder expectations and standards, or which are perceived to have not responded appropriately, may suffer from reputational damage and result in the business, financial condition and/or stock price of a company being materially and adversely affected. Further, this increased focus on ESG issues may result in new regulations and/or third-party requirements that could adversely impact our business, or certain stockholders reducing or eliminating their holdings of our stock. Additionally, an allegation or perception that we have not taken sufficient action in these areas could negatively harm our reputation.

Source: Item 1A, 10-K 0001581280-25-000025 vs Item 1A, 10-K 0001628280-24-048262

Accounting Policies182 words changed in this paragraph; it is 34% similar to last year's version.
The Company has an unconditional option company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to performing the first step of the quantitative goodwill impairment test. The company estimates the fair value of its reporting unit by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). For 2025 and 2024, the Company elected to proceed directly to the step-one assessment which indicated that the fair value of its single reporting unit substantially exceeded the carrying value.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001581280-25-000025 vs Item 8, Note 2 – Summary of significant accounting policies, 10-K 0001628280-24-048262

Legal Proceedings90 words changed in this paragraph; it is 86% similar to last year's version.
On December 12, 2022, a putative securities class action lawsuit captioned Peters v. Twist Bioscience Corporation, et al., Case No. 22-cv-08168 (N.D. Cal.) (“Securities Class Action”) was filed in federal court in the Northern District of California (“Court”) against the Company, its Chief Executive Officer, and its Chief Financial Officer (the “Defendants”) alleging violations of federal securities laws. The Securities Class Action’s claims are based in large part on allegations made in a report issued on November 15, 2022 by Scorpion Capital (“Scorpion Report”) concerning, among other things, the Company’s DNA chip technology and accounting practices. The initial complaint filed in the Securities Class Action alleges that various statements that the defendants Defendants made between December 13, 2019 and November 14, 2022 were materially false and misleading in light of the allegations in the Scorpion Report. The plaintiff who initiated the lawsuit sought to represent a class of shareholders who acquired shares of the Company’s common stock between December 13, 2019 and November 14, 2022 and sought damages as well as certain other costs. On July 28, 2023, the Court appointed a new plaintiff, not the original plaintiff who filed the case, as lead plaintiff in the case and appointed a new law firm as lead counsel. On October 11, 2023, the lead plaintiff filed an amended complaint. The amended complaint is purportedly brought on behalf of all persons other than the Defendants who acquired the Company’s securities between December 20, 2018 and November 15, 2022. The amended complaint alleges that certain statements regarding, among other things, the Company’s DNA products and accounting practices were false and misleading. On December 6, 2023, the Company filed a motion to dismiss the amended complaint and a hearing on the motion to dismiss was held on November 13, 2024. On September 3, 2025, the Court issued an order granting in part and denying in part Defendants’ motion to dismiss and granted the plaintiff leave to further amend by September 24, 2025. The plaintiff did not file a second amended complaint. The Company is engaged in discovery and intends to continue vigorously defending the remaining claims under this action in all respects.

Source: Item 3, via Note 10 – Commitments and Contingencies, 10-K 0001581280-25-000025 vs Item 3, via Note 9 – Commitments and contingencies, 10-K 0001628280-24-048262

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of TWST's Risk Factors and MD&A, 10-K Nov 17, 2025 against 10-K Nov 18, 2024. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
•As we continue to grow our business, we will need to implement new systems and software successfully, otherwise our business and our financial condition and results of operations could be adversely affected;
Read it in 10-K Nov 17, 2025 at sec.gov
AddedRisk Factors
As we continue to grow our business, we will need to implement new systems and software successfully, otherwise our business and our financial condition and results of operations could be adversely affected.
Read it in 10-K Nov 17, 2025 at sec.gov
AddedRisk Factors
We will need to invest in improvements to our operational and IT systems and processes as part of our ongoing effort to improve the overall efficiency and competitiveness of our business, including improvements to prevent increasingly sophisticated cybersecurity incidents and improve standardization, systemization and automation to support growth. Transitioning to these new or upgraded processes and systems requires significant capital investments and personnel resources. Implementation is also highly dependent on the coordination of numerous employees, contractors and software and system providers. While these efforts have resulted in improvements to our operational systems, we expect to continue to incur expenses to implement additional improvements and upgrades to our systems. Many of these expenditures have been and may continue to be incurred in advance of the realization of any direct benefits to our business. Additionally, the effort to gain technological expertise, make use of data analytics, and develop new technologies in our business requires us to incur significant expenses. We cannot guarantee that we will be successful at improving our operational systems, adapting to changes in technology, including the successful utilization of data analytics, AI, and machine learning, or that our efforts will result in the anticipated benefits to us. In addition, the integration of emerging technologies, including data analytics, AI, and machine learning, into our systems and processes may require us to address rapidly developing laws and regulations governing AI. We may also experience difficulties in implementing or operating our new or upgraded operational or IT systems, including, but not limited to, ineffective or inefficient operations, significant system failures, system outages, delayed implementation and loss of system availability, which could lead to increased implementation and/or operational costs, loss or corruption of data, delayed shipments and interruptions of operations resulting in lost sales and/or profits. If our operational or IT system upgrades, improvements and associated implementation efforts are not successful or if we experience unexpected interruption in transition to new or upgraded processes or systems, our financial condition and results of operations could be adversely affected, and our business may become less competitive.
Read it in 10-K Nov 17, 2025 at sec.gov
AddedRisk Factors
AI capabilities may indicate that it could be a significant disruptor in the synthetic biology industry. For example, AI may reduce customer demand for certain types of gene synthesis.
Read it in 10-K Nov 17, 2025 at sec.gov
AddedRisk Factors
The global economy has been impacted by geopolitical tensions. For example, new U.S. federal administration has recently imposed significant new tariffs on imports, which, along with other U.S. trade actions, have triggered retaliatory actions by certain affected countries. These geopolitical tensions could result in, among other things, macroeconomic uncertainty, cyberattacks, supply chain disruptions, higher costs and changes to foreign exchange rates and financial markets. In addition, tariffs and trade restrictions may result in increased production costs and product pricing, supply chain disruptions, limited access to markets and uncertainty related to planning long-term investments and strategies. Additionally, the administration's halt on certain federal research grants may negatively impact our industry. Any prolonged reductions in such funding could slow innovation, delay collaborations and limit the adoption of new technologies that contribute to our business growth. If these or similar policy changes continue or expand, we may face increased costs or impact on the demand for our products. We are monitoring and evaluating any potential impacts that global economic conditions and other policy changes may have on our business, and we are considering ways in which we may offset any impacts. However, there is no assurance that we will be successful in mitigating the effects in the current environment. Although we cannot predict the full extent of these impacts, any such policy changes could adversely affect our business, financial condition and results of operations.
Read it in 10-K Nov 17, 2025 at sec.gov
AddedRisk Factors
In May 2025, we completed the spin out of our DNA data storage application to a new independent company, Atlas Data Storage (“Atlas”), which allows us to focus on our synthetic biology, NGS and biopharma products and services. While we will retain an equity interest in Atlas and receive potential milestone payments and royalties on any future sales of Atlas’ products and services, we may not achieve some or all of the anticipated benefits of the spin out if Atlas’ technology development and commercialization efforts are not successful. In addition, the divestiture reduces business diversification and may prove not to be a superior alternative to the continued development of the DNA data storage application by us. Further, we are providing transition services to Atlas throughout a transition period, including use of some of our facilities and employee services which may
Read it in 10-K Nov 17, 2025 at sec.gov
Show the other 69
AddedRisk Factors
We are subject to data privacy and data protection laws, rules, and customer-imposed controls as a result of producing, collecting, processing, storing and transmitting confidential, personal and/or sensitive data in the course of our business. A significant number of countries where we operate have enacted privacy or data protection laws, rules and regulations, creating significant compliance challenges as we seek to maintain our global reach. In some cases, there are restrictions on the transfer of personal data outside the home country. More recently, privacy and data protection regulators are paying special attention to emerging issues linked to new digital technologies, such as the use of AI, biometrics, and surveillance technologies, which pose unique challenges to existing privacy and data protection paradigms. Any actual or perceived noncompliance could result in significant consequences, including, business interruption, sanctions and significant pecuniary fines, regulatory inquiries and investigations, adverse publicity, loss of competitive advantage and customer trust, as well as privacy litigation and civil lawsuits with damages, any of which may adversely affect our business, reputation and financial statements.
Read it in 10-K Nov 17, 2025 at sec.gov
RemovedRisk Factors
Since our inception, substantially all of our resources have been dedicated to the development of our DNA synthesis platform and our sample preparation kit for NGS. We believe that we will continue to expend substantial resources for the foreseeable future as we continue to expand our production capabilities and enter additional markets we may choose to pursue, including new COVID-19 testing products, pharmaceutical biologics drug discovery and digital data storage in DNA. These expenditures are expected to include costs associated with research and development, increasing manufacturing capabilities, including operating costs of our new Wilsonville, Oregon facility, and increasing supply capabilities as well as marketing and sales capabilities of existing and new products. In addition, other unanticipated costs may arise.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedRisk Factors
•delay, limit, reduce or terminate our establishment of marketing and sales capabilities or other activities that may be necessary to generate revenue and achieve profitability.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedRisk Factors
Our future revenue growth and market potential may depend on our ability to leverage our DNA synthesis platform together with our custom libraries and other proprietary tools, such as our antibody discovery and optimization platform, in adjacent businesses such as pharmaceutical biologics drug discovery and digital data storage in DNA. There can be no assurance that we can continue to utilize our biopharma services offerings to accelerate the lead identification and lead optimization steps of antibody discovery or to discover more effective antibody drugs. In addition, our technology may not develop in a way that allows data storage in DNA to become cost competitive with traditional data storage media or in a way that otherwise enables us to address the markets opportunities that we believe exist. If we are unable to expand into adjacent addressable markets, our business, financial position and results of operations could be negatively impacted.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedRisk Factors
a result, revenue from these sources may vary significantly due to factors that can be difficult to forecast. Any delay or reduction in purchases by customers and potential customers or our inability to forecast fluctuations in demand could harm our future operating results.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedRisk Factors
assurance that we will undertake or successfully complete any collaborations, any transactions that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial condition, results of operations and prospects. Conversely, any failure to enter into any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our products and technologies.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedRisk Factors
We believe that developing and maintaining our brand is important to our success and that our financial success is influenced by the perception of our brand by our customers. Furthermore, the importance of our brand recognition may become even greater to the extent that competitors offer more products similar to ours. Many factors, some of which are beyond our control, are important to maintaining our reputation and brand. These factors include our ability to comply with ethical, social, product, labor and environmental standards. Any actual or perceived failure in compliance with such standards could damage our reputation and brand.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedRisk Factors
additional regulatory controls including enforcement action, administrative and judicial sanctions, all of which could adversely affect our business, financial condition, or results of operations. See "Business-Government regulation-FDA".
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedRisk Factors
Sales to our customers are generally made on open credit terms. Management maintains an allowance for potential credit losses. If our customers’ cash flow, working capital, financial conditions or results of operations deteriorate, they may be unable or even unwilling to pay trade receivables owed to us promptly or at all. As a result, we could be exposed to a certain level of credit risk. If a major customer experiences, or a significant number of customers experience, financial difficulties, the effect on us could be material and have an adverse effect on our business, financial condition and results of operations.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedRisk Factors
Patents have a limited lifespan. Patent terms may be shortened or lengthened by, for example, terminal disclaimers, patent term adjustments, supplemental protection certificates, and patent term extensions. Although extensions may be available,
Read it in 10-K Nov 18, 2024 at sec.gov
RewordedRisk Factors
We While we expect that our existing cash and cash, cash equivalents will be and short-term investments are sufficient to fund our planned operating expenses, capital expenditure requirements and debt service payments through at least the next 12 months. months, our operating plan may change as a result of factors currently unknown to us, and as a result, we have sought and may in the future need to seek additional funds sooner than planned.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedRisk Factors
If adequate funds are not available to us on a timely basis, we may be required to: to delay, limit, reduce or terminate our manufacturing, research and development activities, marketing and sales capabilities or other activities that may be necessary to generate revenue and achieve profitability.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedRisk Factors
Our technology and the production process for our DNA synthesis equipment and tools are complex, involving specialized parts, and we We may encounter unexpected difficulties in the manufacture, improvement manufacturing, improving or increasing the capacity of our DNA synthesis equipment and tools, and addressing these difficulties may cause us to divert our time and resources from our other product offerings.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedRisk Factors
We have established an international trade compliance program that encompasses best practices for preventing, detecting and addressing noncompliance with international trade restraints; however, we could fail to observe the compliance program requirements in a manner that leaves us in noncompliance with export controls or other international trade restraints.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedRisk Factors
Accordingly, our Our guidance is only an estimate of what management believes is realizable as of the date of release. release, and some or all of the assumptions underlying the guidance furnished by us may not materialize or may change significantly.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedRisk Factors
Our inability to continue these initiatives and initiate new research and development efforts could result in a failure to develop or delay in developing new products, improve upon existing products such that sectors such as pharmaceutical biologics drug discovery, DNA library creation and data storage may never be fully developed, and products, or expand our addressable market, which could have a material and adverse impact on our sales, business, financial position and results of operations.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedRisk Factors
In addition, shortages of raw materials or component parts or an increase in the cost of the raw materials or component parts we use could result in decreased revenue or could impair our ability to maintain or expand our business.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedRisk Factors
The Federal Select Agent Program, or the FSAP, FSAP involves rules administered by the Centers for Disease Control and Prevention and Toxins CDC and the Animal and Plant Health Inspection Service APHIS that regulate possession, use and transfer of biological select agents and toxins that have the potential to pose a severe threat to public, animal or plant health or to animal or plant products.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedRisk Factors
If we are required or agree to defend or indemnify any of these third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedRisk Factors
Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent these other companies or institutions from continuing to license intellectual property that we may need to operate our business.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedRisk Factors
Evolving Increasing scrutiny and evolving expectations around corporate responsibility practices, specifically related to environmental, social and governance (“ESG”) matters, from investors, lenders, customers, government regulators and other market participants may impose additional costs and expose us to reputational and other risks.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedRisk Factors
Certain institutional investors, investment funds, other influential investors, customers, suppliers and other third parties are also increasingly focused on ESG practices. practices and corporate social responsibility endeavors and reporting and may use these factors to guide investment strategies.
Read it in 10-K Nov 17, 2025 at sec.gov
Quiet changesRisk Factors
With respect to our Wilsonville facility, if regulatory, manufacturing, or other problems require us to discontinue production at the facility, we will may not be able to manufacture our synthetic genes, oligo pools or selected NGS products or create our DNA libraries, which would adversely impact our business.
Read it in 10-K Nov 17, 2025 at sec.gov
AddedMD&A
As we have moved further up the value chain from fragments to genes to preps to proteins and beyond, the strategic connection between our SynBio and Biopharma products tightens. More customers now leverage both products and services to accelerate discovery and identify breakthrough therapeutics. This growing convergence highlights the power of our integrated platform and reinforces Twist’s unique position to serve the full spectrum of innovation in discovery.
Read it in 10-K Nov 17, 2025 at sec.gov
AddedMD&A
We sold our DNA data storage business to Atlas Data Storage, Inc. ("Atlas"), a newly formed company, that will focus solely on DNA data storage technology and commercialization, with $155.0 million in seed financing round from third-party investors. The purpose of the transaction was to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors. Under the terms of the contribution agreement executed with Atlas, we assigned and licensed our DNA data storage technology to Atlas in exchange of receiving a minority ownership interest upon close, an upfront cash payment and a secured promissory note. We retained an ownership stake in Atlas and may participate in the upside of DNA data storage through future technology and commercial milestone payments, and a revenue share through royalties on future sales of Atlas’ products and services.
Read it in 10-K Nov 17, 2025 at sec.gov
AddedMD&A
•Gross margin increased to 50.7% from 42.6%, mainly due to increase in revenues and holding fixed manufacturing costs relatively flat and driving additional cost savings through continuous process improvement initiatives;
Read it in 10-K Nov 17, 2025 at sec.gov
AddedMD&A
•Loss from operations decreased to $(136.3) million from $(220.8) million primarily due to an increase in both revenues and gross profit for the year ended September 30, 2025, and impairment of long-lived assets recognized in the year ended September 30, 2024. Additional contributing factors were a decrease in research and development expenses offset by an increase in selling, general and administrative expenses for the year ended September 30, 2025;
Read it in 10-K Nov 17, 2025 at sec.gov
AddedMD&A
On October 21, 2024, the Company executed the Royalty Purchase Agreement with XOMA (US) LLC ("XOMA Royalty"). Under the Royalty Purchase Agreement, XOMA Royalty provided Twist Bioscience an upfront payment of $15.0 million in cash in exchange for the right to receive half of the future potential milestone and royalty payments resulting from certain antibody discovery and biopharma services agreements between the Company and its customers (see note 17 of the consolidated financial statements included elsewhere in this Form 10-K).
Read it in 10-K Nov 17, 2025 at sec.gov
AddedMD&A
On May 2, 2025, the Company executed the Contribution Agreement with Atlas for the sale and transfer of its DNA digital data storage assets including the related intellectual property, equipment and contracts and the license of certain other intellectual property and the license of certain other intellectual property for a consideration of 73.0 million shares of Series Seed-1 Preferred Shares of Atlas, upfront cash consideration of $2.5 million, promissory notes of $2.0 million issued by Atlas, contingent manufacturing and commercial milestone payments of up to $75.0 million, and royalty payments based on a percentage of Atlas sales of the DNA data storage products (see note 6 of the consolidated financial statements included elsewhere in this Form 10-K).
Read it in 10-K Nov 17, 2025 at sec.gov
AddedMD&A
On November 13, 2025, we entered into a lease amendment for our facilities in South San Francisco, California. This amendment increases the leased premises by approximately 33,000 square feet in order to consolidate other offices in South San Francisco into a single location and extends the termination date of the lease until June 30, 2036. The amendment also gives us the right, on or before December 31, 2026, to elect to expand the premises to include the entire fourth floor of the building containing approximately 33,000 square feet. For more information, please see Part II, Item 9B and Note 19, Subsequent Events of the notes to our consolidated financial statements included elsewhere in this Form 10-K.
Read it in 10-K Nov 17, 2025 at sec.gov
AddedMD&A
On May 2, 2025, we measured the fair value of our investment in Series Seed-1 Preferred Stock of Atlas using the backsolve method with consideration for a lack of marketability. The backsolve method was used to solve for the implied total equity value based on the May 2025 financing by Atlas to third parties. Consideration was given to the rights and preferences of each of the classes of equity of Atlas and the expected time to a liquidity event. An option pricing allocation method, or OPM, was selected to allocate the total equity value. The OPM treats ordinary shares and preferred shares as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company’s securities changes.
Read it in 10-K Nov 17, 2025 at sec.gov
AddedMD&A
Equity investments held by the Company lack readily determinable fair values and therefore the securities are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar equity securities of the same issuer. We review the carrying value of our equity investments for impairment whenever events or changes in business circumstances indicate the carrying amount of such asset may not be fully recoverable. Impairments, if any, are based on the excess of the carrying amount over the recoverable amount of the asset.
Read it in 10-K Nov 17, 2025 at sec.gov
RemovedMD&A
We believe that the value of orders we receive is a leading indicator of our ability to generate revenue in subsequent quarters, although there can be no assurance orders will translate into revenue. We define an order as a contract with a
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedMD&A
customer or purchase order from a customer, which outlines the promised goods at an agreed upon-price. In some cases, we receive a blanket purchase order from our customers, which includes pricing, payment and other terms and conditions, with quantities defined at the time each customer subsequently issues periodic releases against the blanket purchase order. We regularly assess trends relating to the value of orders we receive, including with respect to our customer concentration.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedMD&A
Orders may never convert into actual revenue and the timing of delivery of our orders and recognition of revenue, if any, may vary based on the nature of the order, and there can be no assurance that orders will result in recognized revenue. The following table lists the value of orders received during the periods indicated:
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedMD&A
September 30, 2024 as compared to 36.6% for the year ended September 30, 2023 mainly due to increase in revenue and the fixed costs being spread over larger revenue base resulting in an increase in gross margin.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedMD&A
Cost of revenues increased from $119.3 million in the prior year to $155.4 million in the year ended September 30, 2023, an increase of $36.1 million, or 30%. The material costs increase by $14.7 million due to higher volume. Payroll, including stock-based compensation, increased $9.9 million, which included $7.4 million of savings related to the 2023 restructuring plan. Depreciation and amortization increased by $11.9 million associated with the capital investment to increase capacity. The increase in payroll costs and depreciation expenses was primarily due to the build out of the second manufacturing facility located in Wilsonville, Oregon.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedMD&A
A discussion of our research and development expenses for the year ended September 30, 2022 as compared to the year ended September 30, 2021 can be found on page 55 of our 2023 Annual Report.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedMD&A
A discussion of our selling, general and administrative expenses for the year ended September 30, 2022 as compared to the year ended September 30, 2021 can be found on page 55 of our 2023 Annual Report.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedMD&A
There was no change in fair value of contingent consideration and holdbacks for the year ended September 30, 2024, as the contingent consideration and holdbacks liabilities were settled in the prior year. During the year ended September 30, 2023, we recognized a change in the fair value of contingent consideration and holdbacks of $5.5 million and $0.4 million related to the acquisitions of Abveris and iGenomX, respectively. The changes were the result of not achieving the Abveris revenue target for calendar year 2022 and a change in fair value of our stock price.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedMD&A
A discussion of our change in fair value of contingent considerations and holdbacks for the year ended September 30, 2022 as compared to the year ended September 30, 2021, can be found on page 56 of our 2023 Annual Report.
Read it in 10-K Nov 18, 2024 at sec.gov
RemovedMD&A
A discussion of our interest and other income (expense), net for the year ended September 30, 2022 as compared to the year ended September 30, 2021, can be found on page 56 of our 2023 Annual Report.
Read it in 10-K Nov 18, 2024 at sec.gov
RewordedMD&A
We recognized an impairment of intangible assets and property and equipment of $44.9 million related to the Biopharma asset group during the year ended September 30, 2024 (see discussion in critical accounting policies and estimates — impairment of long-lived assets below), as compared to impairment of property and equipment of $6.8 million during the year ended September 30, 2023, related to write-off of lab equipment and leasehold improvements for decommissioned labs and computer software. 2024.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedMD&A
The increase in revenue primarily reflects growth in NGS tools revenue of $45.4 million and $39.0 million, growth in synthetic genes revenue of $19.1 million, including the Express Genes offering, which is primarily attributable to increase $20.9 million and growth in revenues from our customers in the healthcare, industrial chemicals/materials and academic research industries and an increase in the number antibody discovery revenue of customers. $3.1 million.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedMD&A
In fiscal year 2024, 2025, our net cash used in the investing activities was $3.1 $24.8 million primarily as a result of purchases of property and equipment of $28.0 million, offset by the proceeds from the sale of our data storage business of $2.5 million, and the net result of purchases and maturity of investments of $2.0 million and purchases of laboratory property, equipment and computers of $5.1 $0.7 million.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedMD&A
We believe that our existing cash, cash equivalents equivalents, restricted cash and short-term investments are and anticipated cash flows from operations, will be sufficient to fund meet our operating expenses, capital expenditure anticipated cash requirements and debt service payments for more than 12 months from the next 12 months. date of this Form 10-K.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedMD&A
The change in operating assets and liabilities was mainly due to decreases increases in accounts receivable of $8.4 $22.4 million, inventory of $8.0 $4.2 million, prepaid and other current assets of $0.4 $3.7 million, and other non-current assets of $0.4 million, accounts payable of $11.8 million and other liabilities $2.3 $1.6 million, offset by increases in accounts payable, accrued expenses of $4.4 million expenses, and accrued compensation of $7.9 $12.7 million and other liabilities $6.6 million.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedMD&A
The last day of our fiscal year is September 30, and we refer to our fiscal year ended September 30, 2022 as fiscal year 2022 or 2022, September 30, 2023 as fiscal year 2023 or 2023 and our fiscal year ended 2023, September 30, 2024 as fiscal year 2024 or 2024. 2024 and our fiscal year ended September 30, 2025 as fiscal year 2025 or 2025.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedMD&A
Total selling, Selling, general and administrative expenses increased 15% 13% to $247.0 million for the year ended September 30, 2025, as compared to $218.4 million for the year ended September 30, 2024, as compared to $189.7 million for the year ended September 30, 2023. 2024.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedMD&A
Research and development expenses decreased 15% 12% to $80.3 million for the year ended September 30, 2025, as compared to $90.9 million for the year ended September 30, 2024, as compared to the $106.9 million for the year ended September 30, 2023. 2024.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedMD&A
Other income (expense) was $0.9 million in fiscal year 2025, as compared to $2.7 million in fiscal year 2024, as compared to $0.7 million in fiscal year 2023, mainly due to fiscal year 2024 impairment losses on an equity investment. investment recognized in fiscal year 2024.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedMD&A
The increase is primarily attributable to an increase in material costs of $19.0 $9.4 million, due to higher sales volume, volume and an increase in depreciation and amortization stock-based compensation expense of $3.2 million primarily due to the capital investment to increase manufacturing capacity in prior years. $3.0 million.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedMD&A
Interest income increased 7%, decreased 26%, to $15.3 $11.4 million in the year ended September 30, 2024, 2025, as compared to $14.4 $15.3 million for the year ended September 30, 2023, resulting from our cash and 2024, due to lower cash equivalents and short-term investments balance. balances and lower interest rates.
Read it in 10-K Nov 17, 2025 at sec.gov
RewordedMD&A
We also enter into Our Biopharma revenue consists of research and development agreements that do not may include up-front payments, milestone payments, or milestone-based payments and recognize revenue on these types of agreements based on the timing of the development activities.
Read it in 10-K Nov 17, 2025 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TWST/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.